Cargando…

Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors

Gastrointestinal stromal tumors (GISTs) are frequently driven by auto-activated, mutant KIT and have durable response to KIT tyrosine kinase inhibitor. However, acquired resistance is an increasing clinical issue in GIST patients receiving front-line imatinib therapy. Our previous studies showed the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsueh, Yuan-Shuo, Chang, Hui Hua, Shan, Yan-Shen, Sun, H. Sunny, Fletcher, Jonathan Alfred, Li, Chien-Feng, Chen, Li-Tzong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756115/ https://www.ncbi.nlm.nih.gov/pubmed/31363162 http://dx.doi.org/10.1038/s41388-019-0900-9

Ejemplares similares

MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2014)

Selecting Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor with Secondary KIT Activation-Loop Domain Mutations
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2013)

Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2013)

KIT and PDGFRA Variants and the Survival of Patients with Gastrointestinal Stromal Tumor Treated with Adjuvant Imatinib
por: Joensuu, Heikki
Publicado: (2023)

TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
por: Saito, Yurina, et al.
Publicado: (2019)

Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors
por: Edris, Badreddin, et al.
Publicado: (2013)

Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-kit mutation
por: IRIE, Mitsuhiro, et al.
Publicado: (2015)

Impact of the KIT/PDGFRA genotype on prognosis in imatinib‐naïve Japanese patients with gastrointestinal stromal tumor
por: Cho, Haruhiko, et al.
Publicado: (2021)

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors
por: Gao, Jing, et al.
Publicado: (2016)

Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor
por: Yim, Eunjung, et al.
Publicado: (2018)

Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours
por: Huang, Mengyuan, et al.
Publicado: (2019)

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation
por: Wakai, T, et al.
Publicado: (2004)

Imatinib response of gastrointestinal stromal tumor patients with germline mutation on KIT exon 13: A family report
por: Engin, Gulgun, et al.
Publicado: (2017)

Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate
por: Rausch, Jessica L., et al.
Publicado: (2016)

KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
por: Joensuu, Heikki, et al.
Publicado: (2023)

Anti-KIT designer T cells for the treatment of gastrointestinal stromal tumor
por: Katz, Steven C, et al.
Publicado: (2013)

Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib‐induced KIT mutations in gastrointestinal stromal tumours
por: Liu, Juan, et al.
Publicado: (2022)

Frequent KIT Mutations in Human Gastrointestinal Stromal Tumors
por: Xu, Zhi, et al.
Publicado: (2014)

Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)
por: Spitaleri, Gianluca, et al.
Publicado: (2015)

Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors
por: Benjamin, Robert S., et al.
Publicado: (2010)

C-Kit-Negative Gastrointestinal Stromal Tumor in the Stomach
por: Seo, Ho Seok, et al.
Publicado: (2015)

Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors
por: Liu, Feiyang, et al.
Publicado: (2019)

Inhibition of KIT-Glycosylation by 2-Deoxyglucose Abrogates KIT-Signaling and Combination with ABT-263 Synergistically Induces Apoptosis in Gastrointestinal Stromal Tumor
por: Mühlenberg, Thomas, et al.
Publicado: (2015)

KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors
por: Lai, Senyan, et al.
Publicado: (2015)

Budgetary Impact of Treatment with Adjuvant Imatinib for 1 Year Following Surgical Resection of Kit-Positive Localized Gastrointestinal Stromal Tumors
por: Rubin, Jamie L., et al.
Publicado: (2010)

Unraveling the Mechanisms of Sensitivity to Anti-FGF Therapies in Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) Lacking Secondary KIT Mutations
por: Boichuk, Sergei, et al.
Publicado: (2023)

Gastrointestinal stromal tumor with KIT mutation in neurofibromatosis type 1
por: Namgung, Hwan
Publicado: (2011)

Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors
por: Caenepeel, Sean, et al.
Publicado: (2010)

Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis
por: Ke, Hengning, et al.
Publicado: (2016)

KCTD12 is negatively regulated by Kit in gastrointestinal stromal tumors
por: Suehara, Yoshiyuki, et al.
Publicado: (2018)

Morphological Correlates of KIT and PDGFRA Genotypes in Gastrointestinal Stromal Tumour
por: Priya, Valli, et al.
Publicado: (2020)

The role of c-kit and imatinib mesylate in uveal melanoma
por: Pereira, Patricia Rusa, et al.
Publicado: (2005)

Relationship between efficacy of sunitinib and KIT mutation of patients with advanced gastrointestinal stromal tumors after failure of imatinib: A systematic review
por: Xie, Fuming, et al.
Publicado: (2019)

Efficacy of SCF drug conjugate targeting c-KIT in gastrointestinal stromal tumor
por: Zhang, Dengyang, et al.
Publicado: (2022)

Spectrum of the KIT Gene Mutations in Gastrointestinal Stromal Tumors in Arab Patients
por: Faiyaz-Ul-Haque, Muhammad, et al.
Publicado: (2018)

KIT and PDGFRa mutational patterns in Sardinian patients with gastrointestinal stromal tumors
por: Palomba, Grazia, et al.
Publicado: (2020)

Discovery of novel potential KIT inhibitors for the treatment of gastrointestinal stromal tumor
por: Jiang, Lili, et al.
Publicado: (2021)

Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors
por: Obata, Y, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_q0jlgno9oue14kmk8hlu5uo0ir